# Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents

> **NCT05225285** · PHASE3 · UNKNOWN · sponsor: **Federal University of Espirito Santo** · enrollment: 1120 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Inactivated Coronavac/Butantan vaccine
- **BIOLOGICAL:** BNT162b2 (Pfizer)

## Key facts

- **NCT ID:** NCT05225285
- **Lead sponsor:** Federal University of Espirito Santo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-21
- **Primary completion:** 2022-06-21
- **Final completion:** 2023-03-21
- **Target enrollment:** 1120 (ESTIMATED)
- **Last updated:** 2022-02-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05225285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05225285, "Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05225285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*